Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 May;7(3):233-242.
doi: 10.1002/cjp2.201. Epub 2021 Feb 23.

Variability in grading of ductal carcinoma in situ among an international group of pathologists

Affiliations
Multicenter Study

Variability in grading of ductal carcinoma in situ among an international group of pathologists

Maartje van Seijen et al. J Pathol Clin Res. 2021 May.

Abstract

The prognostic value of cytonuclear grade in ductal carcinoma in situ (DCIS) is debated, partly due to high interobserver variability and the use of multiple guidelines. The aim of this study was to evaluate interobserver agreement in grading DCIS between Dutch, British, and American pathologists. Haematoxylin and eosin-stained slides of 425 women with primary DCIS were independently reviewed by nine breast pathologists based in the Netherlands, the UK, and the USA. Chance-corrected kappa (κma ) for association between pathologists was calculated based on a generalised linear mixed model using the ordinal package in R. Overall κma for grade of DCIS (low, intermediate, or high) was estimated to be 0.50 (95% confidence interval [CI] 0.44-0.56), indicating a moderate association between pathologists. When the model was adjusted for national guidelines, the association for grade did not change (κma = 0.53; 95% CI 0.48-0.57); subgroup analysis for pathologists using the UK pathology guidelines only had significantly higher association (κma = 0.58; 95% CI 0.56-0.61). To assess if concordance of grading relates to the expression of the oestrogen receptor (ER) and HER2, archived immunohistochemistry was analysed on a subgroup (n = 106). This showed that non-high grade according to the majority opinion was associated with ER positivity and HER2 negativity (100 and 89% of non-high grade cases, respectively). In conclusion, DCIS grade showed only moderate association using whole slide images scored by nine breast pathologists. As therapeutic decisions and inclusion in ongoing clinical trials are guided by DCIS grade, there is a pressing need to reduce interobserver variability in grading. ER and HER2 might be supportive to prevent the accidental and unwanted inclusion of high-grade DCIS in such trials.

Keywords: ductal carcinoma in situ; grade; interobserver variability; pathology.

PubMed Disclaimer

Figures

Figure 1
Figure 1
DCIS grades by pathologist (y‐axis) and by case (x‐axis). The upper row reflects the majority opinion. (A) Grade 1 or 2 or 3. (B) Grade 1 or 2 versus 3.
Figure 2
Figure 2
The strength of the majority opinion for low, intermediate, and high grade. The bottom row shows the distribution of DCIS grade according to the majority opinion and the upper row the number of pathologists that represent the majority opinion.
Figure 3
Figure 3
ER and HER2 expression in relation to low (grade 1), intermediate (grade 2), and high (grade 3) grade according to the majority opinion and the strength of the majority opinion including the NL (NKI) cases (n = 110) only. neg, negative; pos, positive.

Similar articles

Cited by

References

    1. Schuh F, Biazús JV, Resetkova E, et al. Reproducibility of three classification systems of ductal carcinoma in situ of the breast using a web‐based survey. Pathol Res Pract 2010; 206: 705–711. - PubMed
    1. Thompson AM, Clements K, Cheung S, et al. Management and 5‐year outcomes in 9938 women with screen‐detected ductal carcinoma in situ: the UK Sloane Project on behalf of the Sloane Project Steering Group (NHS Prospective Study of Screen‐Detected Non‐Invasive Neoplasias) 1. Eur J Cancer 2018; 101: 210–219. - PubMed
    1. Bijker N, Peterse JL, Duchateau L, et al. Risk factors for recurrence and metastasis after breast‐conserving therapy for ductal carcinoma‐in‐situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 2001; 19: 2263–2271. - PubMed
    1. Elshof LE, Schaapveld M, Schmidt MK, et al. Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population‐based cohort of 10,090 women. Breast Cancer Res Treat 2016; 159: 553–563. - PMC - PubMed
    1. Visser LL, Elshof LE, Van de Vijver K, et al. Discordant marker expression between invasive breast carcinoma and corresponding synchronous and preceding DCIS. Am J Surg Pathol 2019; 43: 1574–1582. - PubMed

Publication types